-
Policy Matters
Clinical Trials That Reflect Real-world PatientsA recent article discusses challenges and practical solutions for working toward more diverse and equitable oncology clinical trials.
by Nicholas Warren, PhD
-
Making Clinical Trials Easier
Clinical trials can be hard to find, challenging to get into and difficult to complete. Patient advocates and their supporters want to change that.
by Cameron Walker
-
Get Involved
A Bountiful HarvestFood for the Cure provides fresh produce to people with cancer.
by Thomas Celona
-
Policy Matters
Reigniting the MoonshotPresident Biden proposes increased investment in cancer research and prevention to achieve the goals of the revised Cancer Moonshot.
by Roy S. Herbst, MD, PhD
-
Get Involved
Baked GoodnessSyreeta Harrison sells homemade cupcakes to fund care packages for people with cancer.
by Thomas Celona
-
Building Bridges
AACR Scientist↔Survivor Program celebrates 25 years of sparking conversations between cancer patients and researchers.
by Thomas Celona
-
Get Involved
Making Home a HavenDesigning Dreams performs bedroom makeovers for children with cancer.
by Thomas Celona
-
Policy Matters
Early-career Cancer Researchers Return to WashingtonAACR Early-career Hill Day allows associate members to visit Capitol Hill and advocate for medical research funding.
by Matt Gontarchick
-
Policy Matters
Stemming the E-Cigarette EpidemicAn updated AACR-ASCO joint statement recommends steps for policymakers to lower e-cigarette use among youth and young adults.
by Roy S. Herbst, MD, PhD
-
Cervical Cancer: A Global Challenge
Low- and middle-income countries make inroads against a preventable and treatable cancer.
by Erin O’Donnell
Cancer Talk
Immunotherapy Improves Survival in Bladder Cancer
New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
by Laura Gesualdi-Gilmore
Cancer Patients Who Quit Smoking, Even Years After Diagnosis, Live LongerFindings from a recent study support smoking cessation after diagnosis, with the most pronounced effect in those who received treatment within six months of diagnosis.
by Kyle Bagenstose
Delaying Treatment ResistanceAdding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.
by Thomas Celona
2024: The Year in Cancer NewsThe Cancer Today editors share the most impactful reporting on cancer research from 2024.
by Cancer Today staff